SI1341524T1 - Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino - Google Patents

Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino

Info

Publication number
SI1341524T1
SI1341524T1 SI200131006T SI200131006T SI1341524T1 SI 1341524 T1 SI1341524 T1 SI 1341524T1 SI 200131006 T SI200131006 T SI 200131006T SI 200131006 T SI200131006 T SI 200131006T SI 1341524 T1 SI1341524 T1 SI 1341524T1
Authority
SI
Slovenia
Prior art keywords
paste
acid
active ingredient
pharmaceutical preparation
labile active
Prior art date
Application number
SI200131006T
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of SI1341524T1 publication Critical patent/SI1341524T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI200131006T 2000-12-07 2001-12-05 Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino SI1341524T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126828 2000-12-07
EP01991781A EP1341524B1 (en) 2000-12-07 2001-12-05 Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
PCT/EP2001/014253 WO2002045686A2 (en) 2000-12-07 2001-12-05 Pharmaceutical paste comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
SI1341524T1 true SI1341524T1 (sl) 2012-02-29

Family

ID=8170595

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200131006T SI1341524T1 (sl) 2000-12-07 2001-12-05 Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino

Country Status (15)

Country Link
US (1) US7988999B2 (sl)
EP (1) EP1341524B1 (sl)
JP (1) JP4241041B2 (sl)
KR (1) KR20030059314A (sl)
CN (1) CN100536844C (sl)
AT (1) ATE529097T1 (sl)
AU (1) AU2002231654A1 (sl)
BR (1) BR0115985A (sl)
CA (1) CA2430816C (sl)
CY (1) CY1112510T1 (sl)
DK (1) DK1341524T3 (sl)
ES (1) ES2375269T3 (sl)
PT (1) PT1341524E (sl)
SI (1) SI1341524T1 (sl)
WO (1) WO2002045686A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115989A (pt) * 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
JP4109286B2 (ja) * 2003-05-02 2008-07-02 順也 藤森 親水性ブレンドゲル
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
EP2462957B1 (en) * 2003-09-23 2019-04-24 Abyrx, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
CA2554260A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
JP5383183B2 (ja) * 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP2007360B1 (en) * 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP5318770B2 (ja) 2006-10-10 2013-10-16 ウィスコンシン アルムニ リサーチ ファンデイション ***内乳首シーラント製剤、およびこれを用いて、熟成チーズの視覚的欠陥を抑制または除去する方法
CA2716399C (en) * 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
BRPI1016082B1 (pt) * 2009-04-08 2020-12-22 Wisconsin Alumni Research Foundation selante intramamário de mamilos
EP2526931B1 (en) * 2011-05-23 2014-12-17 Deva Holding Anonim Sirketi Wet granulation methods of cetyl myristate and/or cetyl palmitate
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3496714A4 (en) 2016-08-11 2020-04-22 Adamis Pharmaceuticals Corporation DRUG COMPOSITIONS.
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
US20220257772A1 (en) * 2019-07-19 2022-08-18 Spi Pharma, Inc. Preparation of lipophilic active ingredients

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
DE69229710T2 (de) * 1991-11-15 2000-03-02 Kanegafuchi Kagaku Kogyo K.K., Osaka Esterbindung enthaltende Polymere für pharmazeutische Zubereitungen
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US20010051131A1 (en) * 1996-06-19 2001-12-13 Evan C. Unger Methods for delivering bioactive agents
EP1019061A4 (en) * 1997-01-29 2006-08-23 Univ Johns Hopkins UREASE-DEPENDENT ADMINISTRATION SYSTEMS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
EA004683B1 (ru) 1999-02-23 2004-06-24 Мерк Энд Ко., Инк. Фармацевтическая композиция, содержащая омепразол
DE60021570T2 (de) 1999-06-07 2006-05-24 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
CA2406864A1 (en) * 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6606234B1 (en) * 2000-09-05 2003-08-12 Saint-Gobain Ceramics & Plastics, Inc. Electrostatic chuck and method for forming an electrostatic chuck having porous regions for fluid flow
DK1341528T3 (da) * 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
DE60130917T2 (de) * 2000-12-21 2008-07-17 Alrise Biosystems Gmbh Induziertes phasenübergangsverfahren zur herstellung von hydrophile wirkstoffe enthaltenden mikropartikeln
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof

Also Published As

Publication number Publication date
AU2002231654A1 (en) 2002-06-18
CN1479611A (zh) 2004-03-03
WO2002045686A2 (en) 2002-06-13
PT1341524E (pt) 2011-12-30
DK1341524T3 (da) 2012-01-16
KR20030059314A (ko) 2003-07-07
ES2375269T3 (es) 2012-02-28
ATE529097T1 (de) 2011-11-15
CY1112510T1 (el) 2015-12-09
US20040101558A1 (en) 2004-05-27
US7988999B2 (en) 2011-08-02
CA2430816C (en) 2012-05-15
BR0115985A (pt) 2003-12-23
CA2430816A1 (en) 2002-06-13
WO2002045686A3 (en) 2002-12-12
JP2004514733A (ja) 2004-05-20
JP4241041B2 (ja) 2009-03-18
EP1341524A2 (en) 2003-09-10
CN100536844C (zh) 2009-09-09
EP1341524B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
SI1341524T1 (sl) Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
HUP0000976A2 (hu) Protonpumpa inhibitort tartalmazó, több egységből pezsgőtablettává préselt gyógyszeradagolási formák
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
MY127350A (en) Flash-melt oral dose formulations
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
TWI264311B (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
IL150528A0 (en) Ibuprofen containing active agent preparation
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
EP1352657A4 (en) INTERFERON-BASED EFFECT POTENTIALIZING THERAPEUTICS
WO2004030684A3 (en) Kavalactone product
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2003013441A3 (en) Levothyroxine compositions and methods
WO2004014318A3 (en) Levothyroxine compositions and methods
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms